Alerta

SARS-COV-2 VARIANTS OF CONCERN-SPECIFIC MULTI-ANTIGENS UNIVERSAL VACCINE

Resumen de: US2025360201A1

Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CDS T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and/or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and/or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).

6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES

Resumen de: US2025360134A1

The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and/or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).

PAN ANTIBODIES AGAINST SARS-COV-2 SPIKE PROTEIN AND USES THEREOF FOR THERAPEUTICAL PURPOSES

Resumen de: WO2025242732A1

The present invention relates to the treatment of the COVID-19, here, the inventors generated potent non-neutralizing pan-SARS-CoV-2 mAb, notably the antibody C10, targeting a conserved region of the virus. Noteworthy, C10 demonstrated remarkable efficacy in recognizing nearly all known variants of the virus and effectively binding infected cells. Leveraging this pan-SARS-CoV-2 mAb, they have engineered CAR-T cells capable of efficiently killing lung epithelial cells infected with the virus. Overall, their work identifies a pan-SARS-Cov-2 able to target bona fide infected cells and provides a proof-of-concept for the potential use of CAR-T cell therapy in combating SARS-CoV-2 infections. Their findings also highlight the potential of non-neutralizing mAbs in mediating immune protection against emerging infectious diseases. Thus, the present invention relates to anti-spike antibodies, particularly in a purified form or in an isolated form and their use to treat SARS-CoV-2. Particularly, the present invention is defined by the claims.

PROTEASE-RESPONSIVE SURFACE-POTENTIAL-TUNABLE PEPTIDE CONSTRUCTS FOR SELECTIVE IMAGING AND ACCURATE INHIBITOR SCREENING

Resumen de: US2025361277A1

In alternative embodiments, provided is a protease-responsive and surface-potential-tunable peptide-conjugated AIEgens (EGTP) for TMPRSS2 selective imaging and accurate inhibitor screening, where EGTP comprises four segments: the first is a polyglutamic acid (Glu, E for short in EGTP) that increases the solubility, blocks the positive charges and cell-penetrating ability of PyTPE; the second comprises a spacer trimylglycine (GGG, G) designed to enhance probe flexibility and reduce steric hindrance for TMPRSS2-substrate interactions; the third component second comprises a TMPRSS2-responsive peptide (QAR, T), which can be cleaved by TMPRSS2 after QAR sequence; and the fourth second comprises a positive charged AIEgens (PyTPE, P). In alternative embodiments, provided are main protease (Mpro)-responsive and modular-peptide-conjugated probes for the selective imaging and inhibition of SARS-CoV-2 infected cells via enzyme-instructed self-assembly and aggregation-induced emission.

PEPTIDE, ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF SPECIFICALLY BINDING TO ACE2 RECEPTOR, AND COMPOSITIONS FOR PREVENTING SARS-COV-2 CONTAINING THE SAME

Resumen de: US2025361316A1

Disclosed are a peptide, an antibody, or an antigen-binding fragment thereof, which specifically binds to an ACE2 (angiotensin-converting enzyme 2) receptor, and a composition for preventing SARS-CoV-2, the composition comprising the same. The peptide includes at least one peptide sequence selected from a group consisting of SEQ ID NO: 1 GHPVNSVLLDF, SEQ ID NO: 2 GHPRVNVGGDF, SEQ ID NO: 3 GVLGPRLLIDY and SEQ ID NO: 4 DGPINRTTIDY.

VIRAL STRAIN SEROLOGY ASSAYS

Resumen de: US2025362296A1

The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.

PREPARATION AND USE OF MRNA VACCINE AND RECOMBINANT PROTEIN SUBUNIT VACCINE AGAINST SARS-COV-2 OR MUTANT

Resumen de: EP4653011A1

Provided in the present invention is a recombinant protein vaccine and/or an mRNA vaccine for preventing and/or treating infections of SARS-CoV-2 or a mutant thereof, and particularly provided is a method of using the mRNA vaccine and the recombinant protein vaccine. The vaccine can induce the generation of an antibody response and a cellular immune response in vivo to block the binding of the S protein of SARS-CoV-2 to the ACE2 receptor of host cells, so that the host resists coronavirus infections.

DIAGNOSTIC TESTING APPARATUS AND SYSTEM

Resumen de: ZA202502303B

A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.

METHOD FOR POLARIZATION-INTERFERENCE REPRODUCTION OF LINEAR BIREFRINGENCE MAPS OF SUPRAMOLECULAR NETWORKS OF DEHYDRATED BLOOD FILMS OF PATIENTS WITH A HISTORY OF COVID-19

Resumen de: UA161330U

Method for polarization-interference reproduction of linear birefringence maps of supramolecular networks of dehydrated blood films of patients with a history of COVID-19 using multichannel laser polarization matrix mapping for algorithmic reproduction of integrally averaged linear birefringence maps of structural anisotropy of supramolecular networks of polycrystalline films of biological fluids and statistical evaluation of their structure. Samples of dehydrated blood films of patients with a history of COVID-19 are placed in the optical arrangement of a polarization Mach-Zahnder interferometer. A series of linearly polarized and circularly left- and right-polarized irradiating and reference laser beams are formed. For each polarization state, the irradiating beam is sequentially directed by a rotating mirror onto a sample of a dehydrated blood film, the laser images of which are projected by a polarization microlens into the plane of the photosensitive pixels of a digital camera. A series of reference beams are sequentially directed into the plane of the laser image of the dehydrated blood film using a rotating mirror, and interference patterns are formed that are transmitted by a linear polarizer in two rotations of the transmission plane to angles of 0° and 90°, which are sequentially recorded by the photosensitive pixels of a digital camera, with subsequent algorithmic digital holographic reproduction of layer-by-layer maps of linear birefringence of the structural an

ANTISENSE MOLECULES AND THEIR USES FOR THE TREATMENT OF CORONAVIRUS INFECTION, IN PARTICULAR THE TREATMENT OF COVID-19 RELATED TO SARS-COV-2 INFECTION

Resumen de: WO2024153586A1

The present invention relates to a new antisense oligonucleotide, a pharmaceutical composition comprising it and their use for preventing or treating infection by coronavirus, especially by SARS-CoV-2 virus which causes the infection disease COVID-19.

PROTEIN AND VACCINE FOR RESISTING INFECTION FROM SARS-COV-2 OMICRON MUTANT STRAIN AND SUBTYPE THEREOF

Resumen de: EP4653454A1

The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-CoV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effective prevention and treatment for infections from the SARS-CoV-2 Omicron mutant strain and the subtype thereof, the present invention provides the protein and the vaccine for resisting infection from the SARS-CoV-2 Omicron mutant strain and the subtype thereof. The vaccine is optimally designed on the basis of an RBD sequence in an S protein of the SARS-CoV-2 Omicron mutant strain and substrains BA.4/5, BQ.1.1, and XBB.1.5, can help a host to resist a coronavirus infection, and particularly has a relatively good prevention and treatment effect on a cross infection caused by a SARS-CoV-2 Omicron mutant strain and subtype viruses thereof.

ANTIBODY SPECIFICALLY BINDING TO IL-10 RECEPTOR AND USE THEREOF

Resumen de: EP4653459A1

The present invention relates to an antibody specifically binding to an IL-10 receptor and use thereof. The antibody targets IL-10 signaling and has an excellent effect of suppressing cytokine storm and excessive inflammation in severe inflammatory infectious diseases, and in particular, can be effectively used in suppressing inflammatory responses in severe SARS-CoV-2 infection and fatal SFTSV infection.

MULTI-EPITOPE CONSTRUCT

Resumen de: US2025352640A1

The invention is situated in the field of vaccination therapy. More specifically, the invention relates to a multi-epitope construct comprising nucleic acid sequences encoding peptides or functional variants and fragments thereof derived from a coronavirus. The invention further relates to a combination, polypeptides, or pharmaceutical composition for use in the treatment or prevention a coronavirus in a subject; in particular the SARS-COV-2 virus.

THERAPEUTIC OR PROPHYLACTIC AGENT FOR COVID19 WHICH COMPRISES SELENONEINE

Resumen de: US2025352517A1

An object is to provide a composition for treatment or prevention of an infection caused by SARS-COV-2 (COVID-19). Based on establishment of a screening method for drugs having an inhibitory activity against proteases of SARS-COV2, and discovery of an inhibitory activity of selenoneine against the proteases of SARS-COV2, a composition for treatment or prevention of COVID-19, which composition includes selenoneine, is provided.

WATER-SOLUBLE CANNABIDIOL COMPOSITIONS AND METHOD FOR PREPARATION OF WATER-SOLUBLE CANNABIDIOL

Resumen de: US2025352558A1

The present invention relates generally to a method of formulation of cannabidiol (CBD) a potential anti-inflammatory drug derived from lemon peel (d-limonene). More, particularly, the present invention relates to the enhancement of lipid soluble CBD into water soluble form in order to improve the formulation of the active component while apply in human for medication. The present invention further provides the therapeutic application of the new formulation which either neutralize and/or decreases the capability of the production of cytokines by activated immune cells during inflammatory process and hence alleviate the sufferings of illness like COVID-19 caused by SARSCOV2.

COMPOSITIONS AND METHODS USING TETRAHYDROCANNABINOL AND COMPOSITIONS INCLUDING SAME FOR TREATING INDICATIONS INVOLVING INFLAMMATION

Resumen de: US2025352561A1

Compositions and methods for treating any one of the disclosed indications involving inflammation in a subject in need thereof, which includes administering to the subject a therapeutically effective amount of a composition including a tetrahydrocannabinol (THC) constituent. The composition is beneficial in reducing inflammation and/or inhibiting the production of pro-inflammatory cytokines and/or converting inflammatory M1 phenotype macrophages into anti-inflammatory M2 phenotype macrophages. It is useful in treating indications such as COVID-19, PASC/long COVID, effects related to ROSC, exposure to chemical or biological weapons, chemotherapy side effects, graft versus host disease, kidney damage from inflammation, chronic obstructive pulmonary disease, aging, and ARDS resulting from COVID-19, mechanical ventilation, shock, sepsis. In further embodiments, the composition may further include fluvoxamine, melatonin, or other disclosed constituents.

METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS

Resumen de: US2025352527A1

Disclosed herein are new therapeutic methods comprising administering compounds that can stabilize HIF and inhibit HIF prolyl hydroxylase (HIF-PH). In particular, methods described herein can be useful for treating/preventing a disease or condition in patients in need thereof, such as a patient having a viral infection such as a respiratory and/or pulmonary viral infection (e.g., an infection such as COVID-19 or a coronavirus infection). Methods described herein can also be useful for treating/preventing organ injury (e.g. organ injury that occurs concurrently or as a result of an infection). For example, methods described herein can be useful for treating or preventing acute lung injury, acute respiratory distress syndrome (ARDS), cardiovascular injury, injury to the liver, kidney diseases, and/or multi-organ failure.

IMPROVED COVID ANTIGEN CODING SEQUENCES

Resumen de: WO2025240699A1

Codon-optimized nucleic acids encoding the XBB 1.5 or KP.2 SARS-CoV-2 protein and their use are provided.

SARS-COV-2 POLYPEPTIDE, ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF

Resumen de: US2025347699A1

This disclosure relates to a method of expressing the receptor-binding domain (RBD) region of the coronavirus SARS-CoV-2 Spike protein in a highly native form that is strongly reactive to natural antibodies induced upon SARS-CoV-2 infection or vaccination of humans and that more efficiently binds the angiotensin-converting enzyme 2 (ACE2) receptor. This method fuses the RBD to the C-terminus of an N-terminal fragment of the gp70 protein (the surface protein (SU) of the Friend57 strain of murine leukemia viruses). This method of expression enhances the native folding of the RBD and increases its recognition by antibodies present in immune sera and its ability to interact with the ACE2 receptor. Further disclosed are methods of using this form of RBD for various purposes.

Protective Apparatuses for Minimizing Risk of Transmission of Infection and Associated Systems and Methods

Resumen de: US2025344786A1

Disclosed herein are protective apparatuses for minimizing the risk of transmission of SARS-CoV-2 and other infectious diseases between individuals in close proximity to one another. Said apparatuses may comprise a receiving component comprising a first aperture comprising a series of flanges; as well as a substantially transparent shield component. Protective apparatuses of the present disclosure may be used to protect dentists and other healthcare workers from transmission of infectious agents and likewise may be used to protect patients in the same manner. Also disclosed herein are systems comprising such protective apparatuses installed to a substantially cylindrical suctioning device such as a vacuum hose or operatively attached to an articulating mechanical arm. Also disclosed herein are methods of using such protective apparatuses and systems to mitigate the risk of transmission of infectious diseases between, without limitation, patients and healthcare workers treating such patients.

GLYCEROPHOSPHOINOSITOL IN PREVENTING AND TREATING COVID-19 INFECTIONS AND METHOD FOR OBTAINING IT

Resumen de: US2025346615A1

Glycerophosphoinositol (GPI) is used in preventing and treating COVID-19 infections. An environmentally sustainable method is for obtaining glycerophosphoinositol. In particular, a process for preparing glycerophosphoinositol from crude or partially purified phospholipid mixtures, includes in sequence: a) hydrolysis of a crude or partially purified phospholipid mixture by treatment with PLA1 and PLA2 enzymes; b) microfiltration of the mixture from step a) and subsequent ultrafiltration and nanofiltration of the microfiltrate to give a concentrated aqueous fraction of reaction products; c) electrodialysis of the aqueous fraction of step b) for separating ionic compounds from neutral compounds; d) ion exchange chromatography. Moreover, glycerophosphoinositol is used in preventing and treating a COVID-19 syndrome.

HIP/PAP PROTEIN OR A DERIVATIVE THEREOF FOR TREATING A COGNITIVE DISORDER ASSOCIATED WITH ANXIETY DISORDER

Resumen de: AU2024271182A1

The present invention relates to the use of the HIP/PAP protein, or a derivative thereof, in the treatment and prevention, and in particular in the treatment, of a cognitive disorder associated with anxiety disorder(s) in an individual in need thereof, as well as for improving cognition in an individual affected by a neurological disorder associated with anxiety disorder(s) or for alleviating cognitive deficit in an individual affected by a disorder selected from the group consisting of Obsessive-compulsive disorder, Attention deficit disorder, Dementia with Lewy bodies disease, Early onset dementia, Epilepsy-related cognitive dysfunction, Fronto-temporal dementia, Posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar disorder, substance abuse, attention deficit disorders, psychotic disorders and a sars-cov-2 infection, and also in the prevention and/or treatment of diet induced cognitive and anxiety deficits in an individual in need thereof, and in particular high fat diet induced cognitive and anxiety deficits.

SARS-CoV-2 Vaccine Constructs

Resumen de: US2025345415A1

The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.

SARS-COV-2 SUBUNIT VACCINE

Resumen de: US2025345413A1

An immunogenic subunit vaccine antigen which comprises at least two receptor-binding domains (RBDs) of the spike (S) protein of SARS-CoV-2 which are fused to a heterologous immunogenic carrier protein, wherein each of said at least two RBDs has a folded structure in an accessible conformation to bind the human angiotensin-converting enzyme 2 (ACE2) receptor protein.

SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF

Nº publicación: US2025345307A1 13/11/2025

Solicitante:

MEMORIAL SLOAN KETTERING CANCER CENTER [US]
PHILIPPS UNIV MARBURG [DE]
Memorial Sloan Kettering Cancer Center,
Philipps-Universit\u00E4t Marburg

Resumen de: US2025345307A1

Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses (e.g., severe acute respiratory syndrome coronavirus SARS-CoV, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, the virus and its mutant forms that cause COVID-19, Middle East respiratory syndrome coronavirus MERS-CoV), Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.